Triumvira Immunologics, Inc.

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

Executive changes in the off-patent medicines industry throughout 2023 reflected a growing interest in the innovator side of the life sciences sector among leading generics and biosimilars companies.

Triumvira Immunologics, Inc. is hoping to take T-cell based therapies for cancer to the next level with its autologous and allogeneic candidates that co-opt the natural biology of T cells to treat so

In 2023, Viatris Inc. continued its efforts to pivot from off-patent products toward innovative operations, offloading four of its businesses including its six-facility-strong active pharmaceutical